GlassScriptPhysician profile
Cortney Mahony
NPI 1639692916
$3,275.56
in general payments reported to CMS, 2019-2025
34 companies · $794 in 2025
The $794 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $435 · 2023: $590 · 2024: $1,171 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $576.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $381.42 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $340.00 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $223.00 | 2021-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $203.20 | 2022-2025 | |
| Pfizer INC. | $178.29 | 2021-2025 | |
| Amgen INC. | $169.10 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $159.86 | 2023-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $136.64 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $115.16 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $97.21 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $77.85 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.74 | 2022-2024 | Advate |
| Boston Scientific Corporation | $67.95 | 2022-2024 | Watchman Flx, Watchman Access System |
| Exact Sciences Corporation | $52.54 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $42.98 | 2023-2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $37.99 | 2025 | Rexulti |
| Gilead Sciences, INC. | $36.85 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2022-2024 | Jardiance |
| Argenx US, INC. | $28.88 | 2023 | Vyvgart |
| Neurocrine Biosciences, INC. | $23.96 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.72 | 2023 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $22.11 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.22 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.37 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.37 | 2024-2025 | Voquezna |
| Ani Pharmaceuticals, INC. | $17.49 | 2025 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $16.41 | 2023 | Trudhesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2021 | |
| Fresenius USA Marketing, INC. | $14.19 | 2021 | |
| Aurinia Pharma U.S., INC. | $14.01 | 2023 | Lupkynis |
| Acadia Pharmaceuticals INC | $14.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.16 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortney Mahony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.